Haemato-oncological patients receive many red blood cell (RBC) transfusions, however evidence-based guidelines are lacking. Our aim is to quantify the effect of restrictive and liberal RBC transfusion strategies on clinical outcomes and blood use in haemato-oncological patients. A literature search, last updated on 11 August 2016, was performed in PubMed, EMBASE (Excerpta Medica Database), Web of Science, Cochrane, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Academic Search Premier without restrictions on language and year of publication. Randomized controlled trials and observational studies that compared different RBC transfusion strategies in haemato-oncological patients were eligible for inclusion. Risk of bias assessment according to the Cochrane collaboration's tool and Newcastle-Ottawa scale was performed. After removing duplicates, 1142 publications were identified. Eventually, 15 studies were included, reporting on 2636 patients. The pooled relative risk for mortality was 0Á68 [95% confidence interval (CI) 0Á46-1Á01] in favour of the restrictive strategy. The mean RBC use was reduced with 1Á40 units (95% CI 0Á70-2Á09) per transfused patient per therapy cycle in the restrictive strategy group. There were no differences in safety outcomes. All currently available evidence suggests that restrictive strategies do not have a negative impact regarding clinical outcomes in haemato-oncological patients, while it reduces RBC use and associated costs.
Summary
Haemato-oncological patients receive many red blood cell (RBC) transfusions, however evidence-based guidelines are lacking. Our aim is to quantify the effect of restrictive and liberal RBC transfusion strategies on clinical outcomes and blood use in haemato-oncological patients. A literature search, last updated on 11 August 2016, was performed in PubMed, EMBASE (Excerpta Medica Database), Web of Science, Cochrane, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Academic Search Premier without restrictions on language and year of publication. Randomized controlled trials and observational studies that compared different RBC transfusion strategies in haemato-oncological patients were eligible for inclusion. Risk of bias assessment according to the Cochrane collaboration's tool and Newcastle-Ottawa scale was performed. After removing duplicates, 1142 publications were identified. Eventually, 15 studies were included, reporting on 2636 patients. The pooled relative risk for mortality was 0Á68 [95% confidence interval (CI) 0Á46-1Á01] in favour of the restrictive strategy. The mean RBC use was reduced with 1Á40 units (95% CI 0Á70-2Á09) per transfused patient per therapy cycle in the restrictive strategy group. There were no differences in safety outcomes. All currently available evidence suggests that restrictive strategies do not have a negative impact regarding clinical outcomes in haemato-oncological patients, while it reduces RBC use and associated costs.
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Twenty to thirty per cent of all red blood cell (RBC) transfusions in Europe are given to patients with haematological diseases, mostly acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), lymphoma and haemoglobinopathies (Bruun et al, 2016; Tinegate et al, 2016) . In general, RBC transfusions are given to optimize the quality of life (QoL) during disease-or treatment-mediated anaemia and to improve platelet-dependent haemostasis (Ho, 1998; Valeri et al, 1998 Valeri et al, , 2001 . The beneficial effect of RBC transfusion on disease outcomes, however, remains difficult to quantify. This is important, as transfusions may include negative effects on outcome through risk of transmission of infectious diseases and transfusion reactions, and their association with immuno-modulation and iron overload (Klein, 1999; Shander et al, 2009) . Current blood transfusion guidelines still lack high-grade evidence for optimal RBC transfusion strategies in haemato-oncological patients (British Committee for Standards in Haematology Blood Transfusion Task Force 2001; Haas & de Vries, 2011; Carson et al, 2012) , this probably explains why RBC transfusion strategies vary widely amongst haematologists and between centres.
Over the past 20 years, many studies have reported no disadvantages of restrictive compared to liberal RBC transfusion strategies, which has led to guidelines recommending restrictive strategies for non-haemato-oncological patient groups (Hebert et al, 1999; Lacroix et al, 2007; Hajjar et al, 2010; Carson et al, 2011; Villanueva et al, 2013; Holst et al, 2014 Holst et al, , 2015 Robertson et al, 2014) . However, to date, solid data on restrictive RBC transfusion strategies in haematooncological patients is lacking. Although various RBC transfusion strategies, such as lowering haemoglobin triggers and single-unit versus double-unit transfusion have been studied, the individual sample sizes of these studies are too small to draw definite conclusions. We therefore conducted a systematic review including a meta-analysis to quantify the effect of restrictive and liberal RBC transfusion strategies on clinical outcomes and blood use in haemato-oncological patients.
Methods

Literature search
For this systematic review with meta-analysis, a literature search was performed in PubMed (1946 PubMed ( -2016 , EMBASE (xcerpta Medica Database; 1947 , Web of science , Cochrane library (1992 Cochrane library ( -2016 , issues: trials and methods studies), CINAHL (Cumulative Index to Nursing and Allied Health Literature; 1937 ) and Academic Search Premier (1975 with the assistance of a qualified librarian. No restrictions were made on language, year of publication or patient age. Both randomized controlled trials (RCTs) and observational studies were eligible study designs for inclusion in this review. We have searched for all possible relevant clinical outcomes and the use of blood products in haemato-oncological patients. The complete eligibility criteria are listed in Table I . The titles and abstracts of all publications identified by the search were independently evaluated for eligibility by two reviewers. Publications deemed irrelevant by both researchers were excluded. In case of disagreement, a third independent reviewer's opinion determined in-or exclusion for further study. All possible eligible studies were included for full-text review. Furthermore, we searched the reference lists of eligible studies to identify additional relevant publications and contacted researchers who registered a RCT in the clinicaltrials.gov and ISRCTN (International Standard Randomized Controlled Trials Number) registry for possible unpublished data. The search strategy is provided in the supplementary appendix. The search was updated on 11 August 2016.
Risk of bias assessment
Risk of bias was assessed at study level by using the Cochrane collaboration's tool for bias assessment for RCTs (Higgins et al, 2011) . Each item of the Cochrane collaboration's tool was rated as "high", "low" or "unclear". RCTs with a high or unclear risk of bias on the following domains: sequence generation, allocation concealment, incomplete outcome data, selective outcomes reporting and other sources of bias, were excluded from pooling by meta-analysis. A lack of blinding, which is almost impossible in transfusion studies, was allowed.
For observational studies, stars were awarded to the items of the Newcastle-Ottawa quality assessment scale at study level (Wells et al, 2000) . The domains considered in this scale are: (i) selection (e.g. representativeness of the exposed cohort and selection of non-exposed cohort); (ii) comparability of the cohorts on the basis of design or analysis (e.g. whether results were adjusted for possible confounders); (iii) outcome (assessment of outcome measures and adequacy of follow-up). A total of nine stars could be achieved. Studies with less than five stars were classified as a 'high risk of bias'. Additionally, studies were considered as having an 'unclear risk of bias' when they scored zero stars at the comparability domain. The studies with a high risk of bias were excluded from pooling by meta-analysis.
Data extraction and missing data
The data extraction was performed by a first reviewer and checked by a second using a pre-specified data extraction form. When the same data were published more than once, the study with the most complete data was included. Where necessary, mean and standard deviations (SD) were calculated from medians, ranges and quartiles with the assumption of an underlying normal distribution (Wan et al, 2014) . The authors of a publication were contacted when data was identified to be missing or unclear in the published literature. When combined data on benign and malignant haematological diseases were reported, we extracted the data of the malignant haematological diseases separately when possible. When this was not possible, we only included studies if little admixture existed.
Definition of RBC transfusion strategies
A low haemoglobin transfusion trigger, a single-unit transfusion policy and a haemoglobin content-based strategy (in 
Statistical analyses
Statistical analyses were all performed in STATA 14 (StataCorp LP, College station, TX). Statistical heterogeneity was assessed by I 2 tests. Percentages of 25%, 50% and 75% corresponded to a low, moderate and high level of heterogeneity (Higgins et al, 2003) . In case meta-analysis was feasible due to the availability of all needed data, pooled relative risks for dichotomous outcomes and weighted mean differences (WMDs) for continuous outcomes and corresponding 95% confidence intervals (CIs) were calculated using the random effects model of Dersimonian and Laird (1986) . A random effects model was chosen as most conservative analysis method because of the unavoidable differences in patient groups and interventions. Furthermore, in cases of little or no heterogeneity, this model produces similar results as a fixed effects model. Forest plots for pooled data are presented. Reduction in blood use is reported as units per therapy cycle, meaning the number of units given within a whole course of chemotherapy, e.g. remission-induction or consolidation course.
Sensitivity analyses
The Newcastle-Ottawa quality assessment scale is quite strict about assessing comparability; exclusion strategies based on this scale may not always be justified (Hern an et al, 2002) . Therefore, to enable a more complete overview, we performed a pre-specified sensitivity analysis, including the observational studies with an unclear risk of bias due to a 'zero' score at comparability. We did not perform sensitivity analyses regarding patient age because we assume that only the size but not the direction of the effects will change between different age categories.
Results
Search results
After removing duplicates, a total of 1142 publications were identified by the search, of which 1060 did not meet the inclusion criteria and four lacked an abstract. Seventy-eight publications, four RCTs and 74 observational studies, were evaluated for full-text review (Fig 1) . No additional relevant publications were identified when searching the reference lists of eligible studies. A total of 15 remaining publications (four RCTs, one non-randomized intervention trial and ten observational cohort studies) reporting on 2636 patients, were included. These selected publications differed between disease type, study design and type of RBC transfusion strategy. The search strategy is listed in the Supplementary appendix. Two out of three authors of included studies responded to our request for additional information. For one study supplementary data could thus be included in our meta-analysis (Webert et al, 2008) ; information on a registered but withdrawn RCT did not lead to includable results (Jansen et al, 2005) .
Risk of bias assessment
Tables II and III provide information on the bias risk assessment. Two RCTs were classified as 'low risk of bias' (Webert et al, 2008; DeZern et al, 2016) . A lack of blinding in the RCT reported by DeZern et al (2016) was allowed as blinding in transfusion studies is almost impossible. Five 'low risk of bias' observational studies were included (Jansen et al, 2004; Paananen et al, 2009; Berger et al, 2012; Lightdale et al, 2012; Hoeg et al, 2013) and one was excluded because of a high risk of bias (Bishop, 2005) . The data of six studies with a low score on the comparability domain were accounted for in the sensitivity analysis in case their data was suitable for pooling by meta-analysis.
Study characteristics
Table IV depicts the characteristics per study. All studies were published between 2004 and 2016. Although various haematological malignancies were included, 14 of the 15 studies reported results mainly or partly on patients with acute leukaemia receiving either intensive chemotherapy or haematopoietic stem cell transplantation (HSCT). Eight of the 15 studies reported on restrictive (70-97 g/l) versus liberal (80-120 g/l) haemoglobin triggers, three on single-versus double-unit RBC transfusion strategies, one study on both of the former mentioned strategies, and three on computer-based strategies. The large overlap between both strategies was mainly due to one study with a very broad definition of the restrictive strategy (73 up to 97 g/l in presence of anaemia-related symptoms) (Hoeg et al, 2013) . We performed a post-hoc sensitivity analysis excluding this particular study to assure the validity of the results concerning restrictive strategies. When this study was excluded the range of restrictive haemoglobin triggers of the remaining studies was 70-88 g/l. Four studies reported results regarding paediatric patients (Paananen et al, 2009; Bercovitz et al, 2011 ; 
Outcomes
Mortality. Five studies (four observational studies and one RCT), were suitable for meta-analysis on mortality (Jansen et al, 2004; Berger et al, 2012; Lightdale et al, 2012; Hoeg et al, 2013; DeZern et al, 2016) . Figure 2 shows the result of the meta-analysis stratified for study design. The relative risk (RR) for mortality was 0Á68 (95% CI 0Á46-1Á01; 571 patients) in favour of the restrictive RBC transfusion strategies. Hence, restrictive transfused patients had a 32% lower chance of dying as compared to the liberal transfused patients. Heterogeneity between the studies was low, I 2 0Á0% (P = 0Á99).
Similar results were obtained after sensitivity analysis, excluding the study with a broad definition of a restrictive transfusion strategy (Hoeg et al, 2013) , resulting in a RR of 0Á67 (95% CI 0Á41-1Á09). This was also the case after sensitivity analysis including observational studies with an unclear risk of bias according to the Newcastle Ottawa quality assessment scale (Patil et al, 2013 ) with a RR of 0Á71 (95% CI 0Á48-1Á04). The forest plot stratified for 45-60 and 90-100 days mortality is presented in the Supplementary appendix.
Reduction of RBC transfusions. Fourteen studies investigated RBC use. Six of these studies, of which two were RCTs and four were observational studies, reported data which could be pooled by meta-analysis (Jansen et al, 2004; Webert et al, 2008; Paananen et al, 2009; Berger et al, 2012; Lightdale et al, 2012; DeZern et al, 2016) . For three of these studies the means and SDs of the data were estimated from medians (Paananen et al, 2009; Berger et al, 2012; Lightdale et al, 2012) . The observed reduction in blood use for restrictive strategies was a WMD of 1Á40 RBC units (95% CI 0Á70-2Á09; 684 patients, Fig 3) . This is best interpreted as a reduction of 1Á40 RBC units on average for each therapy cycle of a restrictive transfused patient compared to patients receiving transfusions more liberal strategy. Heterogeneity between the studies was moderate (P = 0Á14, I 2 39Á4%). The sensitivity analysis including observational studies with an unclear risk of bias according to the Newcastle Ottawa quality assessment scale (Bercovitz et al, 2011; Mear et al, 2014; Butler et al, 2015) showed similar results: WMD 1Á16 (95% CI   Fig 2. Forest plot mortality. I 2 and P values cannot be calculated for the subtotal of RCTs because only one RCT was included. 95% CI, 95% confidence interval; RCT, randomized controlled trial; RR, relative risk.
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0Á66-1Á67). The results of the studies that could not be included in the meta-analyses are presented in Table IV (Arslan et al, 2004; Atilla et al, 2011; Hoeg et al, 2013; Robitaille et al, 2013; Allameddine et al, 2015) .
Modulation of platelet transfusions. Four studies (one RCT and three observational studies), were suitable for inclusion into the meta-analysis to assess whether the RBC transfusion strategy could have influenced the amount of platelet transfusions (Jansen et al, 2004; Webert et al, 2008; Paananen et al, 2009; Berger et al, 2012) . For two of these studies the means and SDs were estimated from medians (Paananen et al, 2009; Berger et al, 2012) . The WMD of platelet use between restrictive and liberal strategies was 0Á16 (95% CI À0Á52 to 0Á83; 454 patients, Fig 4) . The small point estimate indicates little to no difference. However, the wide 95% CI indicates limited statistical precision to support this conclusion. Heterogeneity between these studies was low (P = 0Á57, I 2 0Á0%). The sensitivity analysis, including the study with an unclear risk of bias according to the Newcastle-Ottawa quality assessment scale (Butler et al, 2015) , did not influence the results: WMD 0Á06 (95% CI À0Á60 to 0Á72).
Safety. Only five of the 15 selected studies have reported on safety outcomes: cardiac events, thromboembolic events and bleeding, respectively (Jansen et al, 2004; Webert et al, 2008; Berger et al, 2012; Robitaille et al, 2013; DeZern et al, 2016) .
One study reported data on cardiac events in AML patients in the first 31 days after start of combination chemotherapy, but no differences were found in incidence of cardiac arrhythmias or cardiac dysfunction between the restrictive and the liberal strategy (Jansen et al, 2004) .
Another RCT (Robitaille et al, 2013 ) compared a haemoglobin trigger of 70 g/l to a haemoglobin trigger of 120 g/l to assess the effect on the length of neutropenia in children undergoing myeloablative HSCT for AML, MDS or immune deficiency. After inclusion of six patients, the study was terminated by the data safety monitoring board because of the occurrence of severe cases of veno-occlusive disease (VOD) in all of the patients assigned to the liberal RBC transfusion group. No data on thromboembolic events were reported in any of the other studies.
Incidence of bleeding was reported by four studies (Jansen et al, 2004; Webert et al, 2008; Berger et al, 2012; DeZern et al, 2016) . No differences in the occurrence of any bleeding or clinically significant bleeding were found between the liberal and restrictive RBC transfusion group in a study of 60 patients (120 g/l vs. 80 g/l), RR 1Á05 (95% CI 0Á87-1Á26) and RR 0Á94 (95% CI 0Á69-1Á27) (Webert et al, 2008) . Also, three other studies reported no differences in the incidence of severe bleeding comparing either a double-and single-unit RBC strategy (Berger et al, 2012) or lowering of the haemoglobin trigger (Jansen et al, 2004; DeZern et al, 2016 ) (see Table IV ). Treatment response. Only two studies (Jansen et al, 2004; DeZern et al, 2016) reported on treatment response of 173 acute leukaemia patients. No differences were observed when comparing restrictive with liberal RBC transfusion strategies (Table IV) .
Costs. Four studies reported on the reduction of costs due to reduction of RBC transfusions (Paananen et al, 2009; Berger et al, 2012; Lightdale et al, 2012 ; Allameddine et al, (Table V) . All studies showed a considerable reduction of costs either per patient or per department.
Quality of life. None of the studies reported on QoL.
Discussion
The results of our meta-analysis suggest that a restrictive RBC transfusion strategy has no negative impact on all-cause mortality in haemato-oncological patients. Patients in the restrictive transfused group tended to have even lower mortality rates. The CI, however, is wide; therefore more patients are needed to confirm or refute such conclusions. Looking at mortality as an outcome, several specific possibilities of bias have to be addressed. Changes over time, such as chemotherapy regimens or infection prophylaxis, which were often not stated in the included studies, may have influenced the result of the meta-analysis on mortality as an outcome. Moreover, intensive chemotherapy and the related transfusion support are mostly applied to patients that have an acceptable performance score and no severe comorbidities; therefore the results cannot be generalized to all patients. General confounding by indication, however, is unlikely given that the patients in either the restrictive or liberal transfusion strategy groups in the included studies were comparable with regard to nature and/or severity of the haematological malignancy.
As expected, restrictive RBC transfusion strategies lead to a reduction in the use of RBC units. As a consequence, less frequent use of blood products will diminish the possible risks of adverse events, such as transmission of infectious diseases, transfusion reactions, immunomodulation and secondary iron overload. Therefore, restrictive RBC strategies will not only reduce costs for the blood products itself, but also costs for nursing and blood bank staff activities, preadministration testing, transport, haemovigilance and the management of adverse events. The real difference in costs is, however, difficult to quantify because data on managing possible adverse events due to low haemoglobin levels as a result of a restrictive strategy are unknown.
On the other hand, restrictive RBC transfusion strategies could lead to lower haematocrit levels as compared with liberal RBC transfusion strategies. While low haematocrit levels have been associated with a higher risk of bleeding (Ho, 1998; Valeri et al, 1998 Valeri et al, , 2001 ) a compensatory increased need for platelet products could therefore be presumed. However, in the studies included in our systematic review, no differences were found in either incidence of bleeding events or in the use of platelet products in the more restrictive versus more liberal RBC transfusion strategies. Again, these studies lack power to draw definite conclusions.
Moreover, more restrictive transfusion strategies and thus lower haemoglobin levels could lead to decreased oxygen supply to the coronary arteries and thus theoretically to more cardiac events. Only one study with a relatively small number of patients addressed this variable as a safety outcome, but did not find a change in incidence of cardiac arrhythmia and cardiac dysfunction. Also, none of the other studies reported on the incidence of myocardial events. Given that reports on comorbidity at baseline are lacking in the included studies, no firm conclusions can be drawn with regard to whether more restrictive RBC transfusion strategies are also safe for haemato-oncological patients with cardiac or pulmonary comorbidities. In patients with sepsis on the intensive care unit, who are partly comparable to intensively treated haemato-oncological patients, no differences in RR for fatal and non-fatal myocardial infarction in restrictive versus liberal RBC transfusion strategies were reported (Holst et al, 2014 (Holst et al, , 2015 .
Finally, lower haemoglobin levels by restrictive strategies might comprise QoL. No studies, however, reported on differences in QoL with regard to RBC transfusion strategies. That is a shortcoming because QoL is a common reason to initiate RBC transfusion. Only one RCT is performed adressing QoL in MDS patients, comparing different haemoglobin triggers (72 g/l vs. 96 g/l) (Jansen et al, 2005) . Unfortunately, this study suffered from a too low accrual to allow definite conclusions on the effect of QoL.
In another study, a strikingly increased incidence of VOD in children undergoing myeloablative bone marrow transplantation (BMT) in the liberal transfusion arm led to a preliminary termination of the study. No other studies have ever reported on haemoglobin levels as a risk factor for VOD and several other confounders might have influenced the occurrence of VOD in this myeloablative BMT setting (Robitaille et al, 2013).
Strengths and limitations
The strength of our analysis is that we have conducted a large literature review including both randomized controlled and observational studies. Additionally, no limitations were made on language and publication date and authors were contacted to supply missing data and to explain ambiguities in their studies. Because data from RCTs on this subject is scarce, the combination with 'low risk of bias' observational studies has given us the opportunity to retrieve all relevant up-to-date data on this subject.
The limitation inherent in the present form of analyses is the heterogeneity in patients and study outcomes. Also in our study, not all data could be pooled and although studies that included both non-malignant diseases or patients with solid tumours were excluded, some admixture still exists.
Another limitation is that not every study reported on the difference in haemoglobin level per treatment arm. Therefore, non-compliance of haematologists to a specific RBC strategy in RCTs might have led to smaller differences in post-transfusion haemoglobin levels in both arms. Theoretically, this would only result in an underestimation of the outcome effect.
Third, despite excluding one observational study, which had a broad definition of a restrictive strategy (up to 97 g/l) (Hoeg et al, 2013) in the sensitivity analysis, an overlap in restrictive versus liberal triggers remains and could have led to smaller differences between groups. Again, in our opinion, this would lead to further underestimation of the outcome effect.
Fourth, the effect of different RBC strategies on clinical outcomes in patients with pre-existing cardiac or pulmonary comorbidity could not be assessed because comorbidity at baseline was not reported in the included studies.
The final limitation involves that, for meta-analyses of continuous outcomes, mean and SDs are required. So, when only median and (interquartile) ranges were reported, we estimated the mean and SD by a formula which assumes a normal data distribution to circumvent this problem (Wan et al, 2014) . Although the best possible estimation from the available data, this, however, need not to be true in all cases.
Future research and conclusion
Fortunately, more insight in QoL and adverse events by either restrictive or liberal RBC transfusions in haematooncological patients will become more evident in the near future. Both the REDDS study in the UK (ISRCTN26088319) and the EnhanceRBC study in Canada (NCT02099669) are investigating restrictive (85-100 g/l) versus liberal (110-125 g/l and 110-120 g/l, respectively) RBC transfusion strategies in MDS patients including QoL. The EnhanceRBC study will also assess the incidence of adverse events of RBC transfusions and transfusion requirements. The Canadian TRIST study will also investigate QoL among other clinical outcomes in patients undergoing either autologous or allogeneic HSCT allocated to a restrictive or liberal haemoglobin trigger (70 g/l vs. 90 g/l) (Tay et al, 2011; NCT01237639) .
There are other on-going studies on RBC transfusion in haemato-oncological patients. In France, Chantepie et al (2015) are investigating the effect of a single-versus doubleunit RBC transfusion strategy on clinical outcomes in patients undergoing remission induction therapy, and autologous or allogeneic HSCT (NCT02461264). The 'REAL study' from Stanworth and colleagues, soon to be opened in the UK and Sweden, will assess the feasibility of conducting a larger RCT on the effect of different haemoglobin triggers (70 g/l vs. 90 g/l) on haemato-oncological patients, including outcomes as overall survival and QoL (Dr. S. Stanworth, National Health Service Blood and Transplant, John Radcliffe Hospital, Oxford, United Kingdom, personal communication).
Hence, in the near future our understanding of the effects of different RBC transfusion strategies on haemato-oncological patients will increase considerably and enable proper evidence-and guideline-based use of RBCs in this patient group. Our systematic review with meta-analysis, although with inherent limitations, is the first to summarize the currently available data on RBC transfusion strategies in haemato-oncological patients as one of the most intensely transfused patient groups.
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